El interés en corto de Viracta Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Viracta Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Viracta Therapeutics (OTC:VIRX) Bolsa, Informe de interés en corto

Viracta Therapeutics

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

EVAX

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AREN

CSTM

GDYN

GEAR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: CSTM, VIRX, EVAX, AREN y GDYN.

5 acciones en el foco este viernes: CSTM, VIRX, EVAX, AREN y GDYN

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

Wedbush analyst Alicia Reese reiterates Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) with a Neutral and maintains $32 price target.

Price Target

Reiteration

Analyst Ratings

Wedbush Reiterates Neutral on Cinemark Holdings, Maintains $32 Price Target

Loop Capital analyst Garik Shmois maintains MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) with a Buy and lowers the price target from $19 to $16.

Citigroup Financial 300% Minupon Princ Protected Nts for Russell 2000 Index

Loop Capital Maintains Buy on MasterBrand, Lowers Price Target to $16

Treasury Secretary Scott Bessent&nbsp;has called on China to take proactive steps towards easing trade tensions while expressing optimism over trade deals with other countries. 
What Happened: Bessent pointed out China&#8217;s higher export rate to the U.S. as a key factor contributing to the current tariff imbalance while speaking to <a href="https://www.cnbc.com/2025/04/28/treasury-secretary-bessent-says-its-up-to-china-to-de-escalate-trade-tensions.html">CNBC</a>. &#8220;They sell five times more to us that we sell to them,&#8221; stated the Treasury Secretary. He also termed the trade relations with China &#8220;complicated.&#8221;
Bessent also shed light on the progress of U.S. trade negotiations, hinting at a potential deal with India. "I would guess that India would be one of the first trade deals we would sign. So watch this space," stated Bessent. 
The Treasury Secretary is also hopeful of trade deals with other countries, including Japan. "We've had many countries come forward and present some very good proposals, and we're evaluating those," he said.
He pointed out that the euro has strengthened against the U.S. dollar since trade tensions began, indicating that European countries are likely worried about the situation.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/45029504/elon-musks-ex-wives-missed-out-on-his-billion-dollar-wealth-heres-why" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s Ex-Wives Missed Out on His Billion-Dollar Wealth — Here&#8217;s Why</a>
Why It Matters: Bessent&#8217;s call for de-escalation comes amidst a series of significant developments in the global trade sphere. China has denied any ongoing trade talks with the U.S., but it has reportedly begun <a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts">exempting </a>some U.S. imports from high tariffs, indicating a possible easing of trade tensions. This move could potentially pave the way for further negotiations and a more balanced trade relationship between the two nations.
Meanwhile, Vice President JD Vance, last week, announced <a href="https://www.benzinga.com/25/04/44919025/jd-vance-finalizes-terms-for-trade-deal-with-indian-prime-minister-modi-trump-wants-america-and-india-to-grow">finalized </a>terms for a trade deal with India, aiming to double bilateral trade to $500 billion by the end of the decade. This deal is expected to focus on job creation, resilient supply chains, and prosperity for workers in both nations.
The developments come in the wake of President Donald Trump&#8216;s recent global duties announcement, which has stirred uncertainty in the markets. Despite this, Trump has opted to maintain a 10% tariff across the board, while delaying harsher levies against individual trading partners for 90 days.
Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) declined 7.26%, while the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) lost 5.69% on a year-to-date basis, amid tariff uncertainties. 
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/news/25/04/45028145/joe-rogan-agrees-with-bernie-sanders-saying-hes-right-that-you-should-be-scared-of-oligarchs-they-shouldnt-b" target="_blank" rel="noreferrer noopener">Joe Rogan Agrees With Bernie Sanders, Saying &#8216;He&#8217;s Right That You Should Be Scared Of Oligarchs; They Shouldn&#8217;t Be Running The Government&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Treasury Secretary Scott Bessent Says It's Up To China To 'De-Escalate' Trade Tensions, India To Be The 'First Trade Deal' To Be Signed

Macro Economic Events

Global

Economics

INDA

Watching Shares Of Stocks In The South Asian Subregion; Reuters Exclusively Reports, Pakistan Defence Minister Says Military Incursion By India Is Imminent; Pakistan Defence Minister Says Pakistan's Military Presence Has Been Reinforced On Border With India; Pakistan Defence Minister Says In A Normal Armed Conflict, Both Countries Should Refrain From Using Nuclear Option

Loop Capital analyst Garik Shmois maintains American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) with a Buy and lowers the price target from $100 to $75.

AMWD

Loop Capital Maintains Buy on American Woodmark, Lowers Price Target to $75

Since bottoming during its Sankhya move in 2009, the S&amp;P 500 has rallied sharply—up nearly 795% from that low and 173% since the beginning of its C4 phase in the Adhishthana Cakra Cycle. Most recently, the index formed the Nirvana level at 5097.855 after completing the 24th weekly bar of its C6 phase. This level now acts as a significant anchor and will guide price behavior over the next twelve phases.
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="854" height="658" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061222/SP-C6-Highlighted.png" alt="S&amp;P 500 Nirvana Level" class="wp-image-11669" style="width:400px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061222/SP-C6-Highlighted.png 854w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061222/SP-C6-Highlighted-300x231.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061222/SP-C6-Highlighted-768x592.png 768w" sizes="(max-width: 854px) 100vw, 854px" /><figcaption class="wp-element-caption">S&amp;P 500 Nirvana Level (Shaded: C6 Phase)</figcaption></figure>
For instance, if the index climbs another 3,000 to 4,000 points and is met with a black swan event, the Nirvana level (5097.855) will act as a magnetic pullback zone, just as it did on the 25th bar of C6, when concerns over tariffs and the global trade war triggered a sharp decline. That drop found support exactly at the Nirvana level, from where buying quickly resumed.&nbsp;
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="754" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel.png" alt="S&amp;P 500 Monthly Channel" class="wp-image-11670" style="width:454px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel-300x189.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel-1024x643.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061334/SP-500-Channel-768x483.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">S&amp;P 500 Monthly Channel</figcaption></figure>
Technically, the index remains within a well-defined bullish channel.
Yet through the lens of Adhishthana Principles, two structural concerns stand out:
<ul>
<li>The index did not form the Yajna pattern in C3</li>
<li>It did not test the Renunciation level in C5 </li>
</ul>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="626" height="420" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061457/SP-500-No-Yajna-Formation.png" alt="S&amp;P 500 No Yajna Formed" class="wp-image-11672" style="width:450px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061457/SP-500-No-Yajna-Formation.png 626w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061457/SP-500-No-Yajna-Formation-300x201.png 300w" sizes="(max-width: 626px) 100vw, 626px" /><figcaption class="wp-element-caption">S&amp;P 500: Absence of Yajna Formation</figcaption></figure>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="660" height="638" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061630/Sp-500-No-renunciation-1.png" alt="S&amp;P 500 Level of Renunciation" class="wp-image-11673" style="width:383px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061630/Sp-500-No-renunciation-1.png 660w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/26061630/Sp-500-No-renunciation-1-300x290.png 300w" sizes="(max-width: 660px) 100vw, 660px" /><figcaption class="wp-element-caption">S&amp;P 500: Level of Renunciation Not Tested</figcaption></figure>
These missing elements create a latent imbalance in the cycle. Although momentum and structure remain positive in the near term, this incomplete alignment suggests the potential for a strong Fall of Artah and Artharthi—a set of two significant corrective moves—beginning around 1 March 2027. Given the steep chart structure, if triggered, this could fracture the current Cakra Cycle and set the stage for the more severe Move of Pralay.
Although the trend remains constructive for now, with a higher-high, higher-low formation intact, long-term portfolio structuring, hedge positioning, and large sell-side block execution should factor in the C7 phase decline beginning in March 2027 and extending into mid-2028. This holds particular relevance for institutional investors, macro strategists, and block trade desks managing long-duration exposure.
While the surface suggests strength, the underlying structure is less certain. The S&amp;P 500 continues its ascent—graceful and soaring—but, like a kite, it dances in a hurricane.&nbsp;
Disclaimer: The above analysis is based on the Adhishthana Principles, a proprietary market theory I developed to interpret cyclical and structural patterns in financial markets.

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

S&P 500: A Kite Dancing In A Hurricane

Loop Capital analyst Rob Sanderson maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and lowers the price target from $900 to $695.

Loop Capital Maintains Buy on Meta Platforms, Lowers Price Target to $695

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>GLD</li>
<li>BULL</li>
<li>WOLF</li>
<li>AAPL</li>
<li>$BTC</li>
<li>HOOD</li>
<li>GOOGL</li>
<li>MAGA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

$BTC

AAPL

BULL

GOOGL

HOOD

MAGA

NVDA

TSLA

WOLF

Top 10 Trending Stocks On WallStreetBets As Of April 28, 2025 (Via Swaggy Stocks)

The Safari Collection is a world-renowned luxury safari company and owner of the Giraffe Manor
This is another leading safari company in Africa that has placed an order with Tembo
The first order was from Asilia Africa announced in February 2025
Tembo's solutions selected to drive sustainable safari experiences across Kenya
LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVPR#NASDAQ">VVPR</a>, the "Company"))) is pleased to announce that its wholly-owned subsidiary, Tembo e-LV, has secured an inaugural order for its EV conversion kits from The Safari Collection, owner of luxury properties in Kenya, including the Giraffe Manor, Sasaab, Sala's Camp and Solio Lodge.

VVPR

Vivopower Subsidiary Tembo e-LV Secures Order For EV Conversion Kits From The Safari Collection

On April 28, 2025, Medicus Pharma Ltd. (the "Company") issued a press release announcing that the Company entered into a binding letter of intent, dated April 26, 2025 (the "Letter Agreement"), pursuant to which the Company has agreed to acquire all of the issued and outstanding shares of Antev Ltd. ("Antev") on a share exchange basis (the "Transaction"). Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Subject to certain assumptions, qualifications and conditions, the Company will negotiate and enter into a definitive agreement with Antev to acquire all issued and outstanding Antev shares, on a fully-diluted basis, in exchange for 2,666,600 common shares of the Company ("Consideration Shares"), representing approximately 19% of the issued and outstanding common shares of the Company as of the date of the Letter Agreement. In addition to resale restrictions prescribed under applicable securities laws, the Consideration Shares will be subject to a 9-month staggered lock-up release and an agreement granting certain voting rights in favor of Company management for a period of 36 months.
Upon the achievement of certain milestones related to potential future U.S. Food and Drug Administration ("FDA") Phase 2 and New Drug Administration approvals, Antev shareholders will be entitled to receive up to approximately US$65 million in additional contingent consideration.

MDCX

Medicus Pharma To Acquire Antev Ltd. For 19% Equity Stake, Or ~2.67M Shares, With Potential $65M In Milestone Payments For Prostate Drug Teverelix

Barclays analyst Brandon Oglenski maintains Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) with a Overweight and lowers the price target from $475 to $290.

SAIA

Barclays Maintains Overweight on Saia, Lowers Price Target to $290

Susquehanna analyst Charles Minervino maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Positive and lowers the price target from $48 to $46.

Susquehanna Maintains Positive on Schlumberger, Lowers Price Target to $46

Avantor Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) reported in-line earnings for its <a href="https://www.benzinga.com/quote/AVTR/earnings">first quarter on Friday</a>.
The company posted adjusted EPS of 23 cents in line with consensus. The life science tools company reported sales of $1.58 billion, missing the consensus of $1.61 billion.
"While earnings and margin performance were in line with our plan, Lab Solutions revenue was impacted by reduced demand – particularly in our Education and Government end market – following recent policy changes," said Michael Stubblefield, president and CEO. "We are updating our full-year outlook to reflect ongoing funding and policy-related headwinds. While we are not satisfied with our current growth trajectory, we are implementing a comprehensive strategy to strengthen our Lab Solutions segment and are committed to moving with urgency to improve performance across the business."
On Friday, Avantor announced that Stubblefield intends to step down as director, president, and CEO. The Board has initiated a search process to identify the company's next CEO.
Avantor shares fell 16.6% to close at $12.93 on Friday.
These analysts made changes to their price targets on Avantor following earnings announcement.
<ul>
<li>Baird analyst Catherine Schulte maintained Avantor with an Outperform and lowered the price target from $21 to $17.</li>
<li>Morgan Stanley analyst Tejas Savant downgraded the stock from Overweight to Equal-Weight and lowered the price target from $25 to $15.</li>
<li>Barclays analyst Luke Sergott maintained Avantor with an Overweight rating and lowered the price target from $18 to $15.</li>
</ul>
Considering buying AVTR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197-1024x562.png" alt="" class="wp-image-890981" style="width:600px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/28092545/image-197.png 1136w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/04/45035424/top-3-health-care-stocks-that-may-rocket-higher-in-april">Top 3 Health Care Stocks That May Rocket Higher In April</a> </li>
</ul>
Photo via Shutterstock

Earnings

AVTR

Avantor Analysts Cut Their Forecasts After Q1 Results

Barclays analyst Lauren Lieberman maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Equal-Weight and lowers the price target from $143 to $135.

Barclays Maintains Equal-Weight on PepsiCo, Lowers Price Target to $135

Susquehanna analyst Joseph Stauff initiates coverage on TKO Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>) with a Positive rating and announces Price Target of $180.

Initiation

Susquehanna Initiates Coverage On TKO Group Holdings with Positive Rating, Announces Price Target of $180

Barclays analyst Seth Sigman maintains O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) with a Equal-Weight and raises the price target from $1250 to $1290.

ORLY

Barclays Maintains Equal-Weight on O'Reilly Automotive, Raises Price Target to $1290

Wedbush analyst Alicia Reese maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Outperform and lowers the price target from $125 to $100.

ROKU

Wedbush Maintains Outperform on Roku, Lowers Price Target to $100

Barclays analyst Lauren Lieberman maintains Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) with a Overweight and raises the price target from $37 to $38.

Barclays Maintains Overweight on Keurig Dr Pepper, Raises Price Target to $38

Q4 and 2024 Year-End Preliminary Unaudited Select Financial Results
<ul>
<li>Expected $72.3 million in cash &amp; cash equivalents and short-term investments as of December 31, 2024 (inclusive of a $18 million credit facility) compared to $85.6 million in cash &amp; cash equivalents and short-term investments as of December 31, 2023 (inclusive of a $15 million credit facility).</li>
<li>Expected U.S. Generally Accepted Accounting Principles (GAAP) net loss in 2024 of $111.8 million, or $7.01 loss per share, compared to $114.2 million, $11.32 loss per share, in 2023.</li>
<li>Expected fourth quarter 2024 GAAP net loss of $37.3 million, or $1.51 loss per share, compared to $38.5 million, or $2.56 loss per share, in Q3 2024 and $35.2 million, or $3.44 loss per share, in Q4 2023. &nbsp;</li>
</ul>
The preliminary results presented reflect the Company's estimates based solely upon information available, and the Company's final results could differ from these estimates due to the completion of the Company's financial closing procedures, final adjustments and other developments that may arise between now and the time such audited consolidated financial statements for the year ended December 31, 2024 are issued. The Company expects to release the fully audited 2024 financial statements on or before May 15, 2025.

Guidance

REE Automotive Provides 2024 Business Update; Reschedules The Release Date Of Its Q4 And FY24 Financial Results To Before The Market Opens On Thursday, May 15, 2025; Sees Q4 EPS $(1.51) Up From $(3.44) YoY

Barclays analyst David Anderson maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Overweight and lowers the price target from $265 to $230.

Barclays Maintains Overweight on Fiserv, Lowers Price Target to $230

Press Releases

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Management

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics Announces New Employment Inducement Grants

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Comments

Viracta Therapeutics

Interés en corto

Viracta Therapeutics (OTC:VIRX) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL